NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ELVN

Enliven Therapeutics Inc

Jul 03 • 04:00PM ET

20.73

Dollar change +0.09
Percentage change 0.44	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL ONC

| Held by: VTI IWM VXF IWO IBB SCHA VTWO IHE IWC VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	34.27%	Shs Outstand	49.04M	Perf Week	-3.67%
Market Cap	1.22B	Forward P/E	-	EPS next Y	-2.44	Insider Trans	-0.92%	Shs Float	38.78M	Perf Month	-5.17%
Enterprise Value	933.67M	PEG	-	EPS next Q	-0.53	Inst Own	61.32%	Short Float	17.07%	Perf Quarter	4.38%
Income	-94.83M	P/S	-	EPS this Y	-10.22%	Inst Trans	0.90%	Short Ratio	13.70	Perf Half Y	-7.41%
Sales	0.00M	P/B	3.53	EPS next Y	-17.12%	ROA	-29.39%	Short Interest	6.62M	Perf YTD	-7.87%
Book/sh	5.88	P/C	4.22	EPS next 5Y	-20.26%	ROE	-31.30%	52W High	30.03 -30.97%	Perf Year	-8.68%
Cash/sh	4.91	P/FCF	-	EPS past 3/5Y	43.93% 19.02%	ROIC	-32.89%	52W Low	13.30 55.86%	Perf 3Y	328.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.03% 7.73%	Perf 5Y	-84.86%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-0.19%	Oper. Margin	-	ATR (14)	1.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.06	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.08	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	21.06	EPS Q/Q	-5.45%	SMA20	-1.12%	Beta	0.93	Target Price	40.44
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	6.35%	Rel Volume	0.56	Prev Close	20.64
Employees	62	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	-6.68%	Avg Volume	483.15K	Price	20.73
IPO	Mar 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.66% -	Trades		Volume	272,510	Change	0.44%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Initiated	Goldman	Buy	$37
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Jun-17-25 01:33PM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey) -5.59%
Jun-16-25 04:05PM	Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.39%
Jun-13-25 09:30AM	Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.44%
06:10AM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
06:02AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress (PR Newswire)
04:05PM	Loading…
May-22-25 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-17-25 12:40PM	Enliven price target lowered to $27 from $36 at JonesResearch (TipRanks)
May-14-25 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire) -10.41%
09:56AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress (PR Newswire)
Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
04:05PM	Loading…
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Loading…
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Jan-01-01 12:00AM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Jul 01 04:42 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '25	Sale	20.91	3,250	67,956	23,000	Jul 01 04:42 PM
Hohl Benjamin	Officer	Jun 27 '25	Proposed Sale	21.52	4,250	91,460		Jun 27 04:01 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Sale	21.40	12,500	267,458	965,188	Jun 24 05:36 PM
Lyssikatos Joseph P	Officer	Jun 20 '25	Proposed Sale	21.57	12,500	269,625		Jun 20 04:02 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 17 '25	Sale	22.18	12,500	277,292	952,892	Jun 18 06:22 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Option Exercise	2.48	3,000	7,440	26,000	Jun 17 04:24 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 13 '25	Sale	22.55	3,000	67,655	23,000	Jun 17 04:24 PM
Kintz Samuel	Officer	Jun 17 '25	Proposed Sale	23.09	12,500	288,625		Jun 17 04:15 PM
Hohl Benjamin	Officer	Jun 13 '25	Proposed Sale	19.99	3,000	59,980		Jun 13 04:08 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 09 '25	Sale	20.34	6,667	135,574	303,309	Jun 11 06:25 PM
Patel Anish	Officer	Jun 09 '25	Proposed Sale	20.74	6,667	138,274		Jun 09 04:21 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jun 03 '25	Sale	20.03	7,500	150,220	977,688	Jun 05 04:55 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 03 '25	Sale	20.05	7,500	150,352	965,392	Jun 05 04:53 PM
Kintz Samuel	Officer	Jun 03 '25	Proposed Sale	19.14	7,500	143,550		Jun 03 05:34 PM
Lyssikatos Joseph P	Officer	Jun 03 '25	Proposed Sale	19.14	7,500	143,550		Jun 03 05:14 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 27 '25	Option Exercise	2.48	3,250	8,060	26,250	May 29 05:38 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 27 '25	Sale	16.18	3,250	52,593	23,000	May 29 05:38 PM
Hohl Benjamin	Officer	May 27 '25	Proposed Sale	16.40	3,250	53,300		May 27 04:03 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 19 '25	Sale	16.31	5,000	81,534	985,188	May 21 06:31 PM
Kintz Samuel	PRESIDENT AND CEO	May 19 '25	Sale	16.49	5,000	82,453	972,892	May 21 06:29 PM
Kintz Samuel	Officer	May 19 '25	Proposed Sale	16.86	5,000	84,300		May 19 04:22 PM
Lyssikatos Joseph P	Officer	May 19 '25	Proposed Sale	16.86	5,000	84,300		May 19 04:21 PM
Patel Anish	CHIEF OPERATING OFFICER	May 07 '25	Sale	18.39	6,667	122,579	309,976	May 09 06:48 PM
Patel Anish	Officer	May 07 '25	Proposed Sale	19.69	6,667	131,273		May 07 04:11 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 01 '25	Sale	20.07	5,030	100,966	992,658	May 05 06:43 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 02 '25	Sale	20.01	2,470	49,424	990,188	May 05 06:43 PM
Kintz Samuel	PRESIDENT AND CEO	May 01 '25	Sale	20.08	5,330	107,007	980,062	May 05 06:42 PM
Kintz Samuel	PRESIDENT AND CEO	May 02 '25	Sale	20.00	2,170	43,409	977,892	May 05 06:42 PM
Lyssikatos Joseph P	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:03 PM
Kintz Samuel	Officer	May 01 '25	Proposed Sale	18.94	7,500	142,050		May 01 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Option Exercise	2.48	3,250	8,060	26,250	Apr 30 06:59 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Apr 28 '25	Sale	18.69	3,250	60,738	23,000	Apr 30 06:59 PM
Hohl Benjamin	Officer	Apr 28 '25	Proposed Sale	18.21	3,250	59,182		Apr 28 04:19 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Apr 21 '25	Sale	16.07	5,000	80,366	997,688	Apr 23 05:09 PM
Kintz Samuel	PRESIDENT AND CEO	Apr 17 '25	Sale	16.42	5,000	82,096	985,392	Apr 21 05:55 PM
Lyssikatos Joseph P	Officer	Apr 21 '25	Proposed Sale	16.53	5,000	82,650		Apr 21 04:28 PM
Kintz Samuel	Officer	Apr 17 '25	Proposed Sale	16.07	5,000	80,350		Apr 17 04:19 PM
Patel Anish	Member of immediate family of	Apr 14 '25	Proposed Sale	16.51	2,010	33,185		Apr 14 04:54 PM
Patel Anish	Member of immediate family of	Apr 14 '25	Proposed Sale	16.51	2,010	33,185		Apr 14 04:48 PM
Patel Anish	CHIEF OPERATING OFFICER	Apr 07 '25	Sale	18.04	6,667	120,269	316,643	Apr 09 04:25 PM
Patel Anish	Officer	Apr 07 '25	Proposed Sale	18.69	6,667	124,606		Apr 07 04:09 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '25	Option Exercise	2.48	3,250	8,060	26,250	Mar 31 07:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 27 '25	Sale	21.33	3,250	69,321	23,000	Mar 31 07:37 PM
Hohl Benjamin	Officer	Mar 27 '25	Proposed Sale	20.58	4,250	87,465		Mar 27 04:01 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 24 '25	Option Exercise	2.48	1,000	2,480	24,000	Mar 26 07:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 24 '25	Sale	22.50	1,000	22,504	23,000	Mar 26 07:37 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Mar 19 '25	Sale	20.61	12,500	257,575	1,002,688	Mar 21 05:49 PM
Kintz Samuel	PRESIDENT AND CEO	Mar 17 '25	Sale	20.83	12,500	260,320	990,392	Mar 19 05:42 PM
Lyssikatos Joseph P	Officer	Mar 19 '25	Proposed Sale	20.28	12,500	253,500		Mar 19 04:18 PM
Kintz Samuel	Member of immediate family of	Mar 18 '25	Proposed Sale	21.04	21,531	453,012		Mar 18 04:14 PM
Kintz Samuel	Member of immediate family of	Mar 18 '25	Proposed Sale	21.04	21,531	453,012		Mar 18 04:06 PM
Kintz Samuel	Officer	Mar 17 '25	Proposed Sale	20.74	12,500	259,250		Mar 17 04:14 PM
Patel Anish	Member of immediate family of	Mar 17 '25	Proposed Sale	20.74	2,500	51,850		Mar 17 04:08 PM
Patel Anish	Member of immediate family of	Mar 17 '25	Proposed Sale	20.74	2,500	51,850		Mar 17 04:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Mar 07 '25	Sale	21.44	6,667	142,936	323,310	Mar 11 05:18 PM
Patel Anish	Officer	Mar 07 '25	Proposed Sale	21.46	6,667	143,074		Mar 07 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 04 '25	Option Exercise	2.48	10,000	24,800	23,000	Mar 06 06:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '25	Option Exercise	2.48	3,250	8,060	16,250	Mar 03 08:07 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 27 '25	Sale	20.41	3,250	66,327	13,000	Mar 03 08:07 PM
Hohl Benjamin	Officer	Feb 27 '25	Proposed Sale	20.28	4,250	86,190		Feb 27 04:10 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 05:02 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 04:17 PM
Patel Anish	CHIEF OPERATING OFFICER	Feb 07 '25	Sale	21.93	6,667	146,206	329,977	Feb 10 05:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 05 '25	Option Exercise	2.48	1,000	2,480	14,000	Feb 07 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 05 '25	Sale	22.52	1,000	22,524	13,000	Feb 07 07:06 PM
Patel Anish	Officer	Feb 07 '25	Proposed Sale	22.47	6,667	149,807		Feb 07 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 27 '25	Option Exercise	2.48	3,250	8,060	16,250	Jan 29 07:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 27 '25	Sale	21.59	3,250	70,178	13,000	Jan 29 07:21 PM
Hohl Benjamin	Officer	Jan 27 '25	Proposed Sale	21.86	4,250	92,905		Jan 27 04:37 PM
Patel Anish	Member of immediate family of	Jan 14 '25	Proposed Sale	22.07	2,500	55,175		Jan 14 04:06 PM
Patel Anish	Member of immediate family of	Jan 14 '25	Proposed Sale	22.07	2,500	55,175		Jan 14 04:01 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Option Exercise	1.81	21,700	39,264	21,700	Jan 10 05:31 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Sale	24.18	21,700	524,697	0	Jan 10 05:31 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Sale	24.17	6,667	161,171	336,644	Jan 10 05:31 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 13 '24	Option Exercise	2.48	13,000	32,240	13,000	Jan 07 04:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 03 '25	Option Exercise	2.48	1,000	2,480	14,000	Jan 07 04:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 03 '25	Sale	25.04	1,000	25,039	13,000	Jan 07 04:43 PM
Patel Anish	Officer	Jan 07 '25	Proposed Sale	24.07	28,367	682,794		Jan 07 04:21 PM
Hohl Benjamin	Officer	Jan 03 '25	Proposed Sale	23.90	1,000	23,900		Jan 03 04:05 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 27 '24	Option Exercise	2.48	3,350	8,308	3,350	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 30 '24	Option Exercise	2.48	900	2,232	900	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 27 '24	Sale	22.15	3,350	74,219	0	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 30 '24	Sale	22.51	900	20,255	0	Dec 31 05:18 PM
Hohl Benjamin	Officer	Dec 27 '24	Proposed Sale	22.71	4,250	96,518		Dec 27 04:33 PM
Patel Anish	Member of immediate family of	Dec 16 '24	Proposed Sale	23.15	2,500	57,875		Dec 16 04:30 PM
Patel Anish	Member of immediate family of	Dec 16 '24	Proposed Sale	23.15	2,500	57,875		Dec 16 04:15 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Option Exercise	2.48	5,250	13,020	5,250	Dec 02 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Sale	24.89	5,250	130,688	0	Dec 02 05:18 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:35 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:28 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Option Exercise	2.48	6,250	15,500	6,250	Oct 30 06:04 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Sale	28.56	6,250	178,485	0	Oct 30 06:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 18 '24	Sale	30.00	716	21,483	343,311	Oct 22 04:23 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 18 '24	Sale	30.00	847	25,413	1,015,188	Oct 22 04:22 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 18 '24	Sale	30.00	924	27,723	1,002,892	Oct 22 04:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Option Exercise	2.48	814	2,019	814	Oct 22 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Sale	30.00	814	24,422	0	Oct 22 04:19 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	817	24,512	123,673	Oct 22 04:18 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	753	22,592	27,165	Oct 22 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience